All News

3 September 2008

Regeneron’s ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering TherapyAntibodies

2 September 2008

MorphoSys Announces Publication of First MOR103 DataAntibodies

31 August 2008

ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results AnnouncedAntibodies

31 August 2008

Novartis decides not to pursue further development of Aurograb(TM)Antibodies

28 August 2008

Arana Announces Key Anti-Inflammatory Drug MilestoneAntibodies

27 August 2008

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) TrialAntibodies

27 August 2008

NICE final guidance recommends Lucentis(R) as cost-effective treatment for wet AMD, a leading cause of blindnessAntibodies

26 August 2008

Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient EnrollmentAntibodies

24 August 2008

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung CancerAntibodies

24 August 2008

Influenza Antibody Spray Success: Opens New Approach to Respiratory Disease ControlAntibodies

22 August 2008

FDA approved Amgen’s TPO peptibody to treat thrombocytopeniaAntibodies

21 August 2008

Boehringer Ingelheim extends research collaboration with Ablynx for Alzheimer’s diseaseAntibodies

21 August 2008

ATS acquires majority shareholding in GANYMEDAntibodies

20 August 2008

Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple MyelomaAntibodies

19 August 2008

Affitech and Omeros Enter Into Antibody Discovery and Development AgreementAntibodies

19 August 2008

Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular DegenerationAntibodies

16 August 2008

Clinical Data Published in ‘Science’ Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody BlinatumomabAntibodies

13 August 2008

Morphotek(R), Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate CancerAntibodies

13 August 2008

Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer CommencesAntibodies

13 August 2008

ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company’s TAP TechnologyAntibodies

12 August 2008

MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alphaAntibodies

11 August 2008

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 AntagonistAntibodies

11 August 2008

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast CancerAntibodies

10 August 2008

FDA Extends Review Timeline for Ustekinumab Biologic License Application Three MonthsAntibodies

7 August 2008

InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625Antibodies

6 August 2008

Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical TrialAntibodies

5 August 2008

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical TrialAntibodies

5 August 2008

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105Antibodies

5 August 2008

YM Biosciences Reports Phase II Data for Nimotuzumab in Metastatic Colorectal CancerAntibodies

3 August 2008

Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

CD40 Agonists & CD40/L Antagonists Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CD73 Inhibitor Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: Claudin 18.2-Targeted Immunotherapeutics

PSMA-Targeted Therapy Pipeline Review